Improvement of glucose and lipid metabolism with pegylated interferon-α plus ribavirin therapy in Chinese patients chronically infected with genotype 1b hepatitis C virus
Improvement of glucose and lipid metabolism with pegylated interferon-α plus ribavirin therapy in Chinese patients chronically infected with genotype 1b hepatitis C virus
Blog Article
BACKGROUND: Many epidemiological studies have demonstrated a significant association between Type 2 diabetes mellitus and abnormal lipid profiles with chronic HCV genotype 1 (GT1) infection.We examined the impact on glucose and lipid profiles of treating Chinese patients using pegylated interferon (Peg-IFN)-α and ribavirin (RBV).METHODS: We conducted a hospital-based clinical study of Chinese patients chronically infected with GT1b HCV.
All the patients were treated for 48 weeks (PR48) with Peg-IFN-α (180 μg once per week) or Peg-IFN-α (1.5 μg/kg once per week) plus RBV (15 mg/kg per day)).Fasting blood glucose (FBG), postprandial blood glucose (PBG-2h), glycosylated hemoglobin helmets (HbA1c), total cholesterol (TC) and triglyceride (TG) levels, were measured at baseline, during therapy, at the end of therapy and at follow-up.
In addition, liver stiffness (LS) by transient elastography, HCV RNA and ALT levels were also measured.RESULTS: We enrolled 116 patients.At the end of treatment (EOT) (week 48), HCV RNA was negative in all patients, 77.
6% (90/116) of patients achieved sustained virologic response (SVR) 24 weeks after EOT, and 22.4% (26/116) Rolling Papers did not achieve SVR.All parameters associated with liver inflammation, liver fibrosis, glucose and lipid metabolism had decreased significantly compared with baseline (P<.
05) in SVR patients.However, there were no obvious changes in lipid metabolism in non-SVR patients.CONCLUSION: PR48 therapy is still the primary treatment for Chinese patients with GT1b HCV infection and will remain so until oral anti-HCV agents are approved.
It is beneficial in amelioration of liver histological status and glucose metabolism regardless of post-treatment virologic response.